FDA
-
-
-
-
-
-
-
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 and Provides Business Update
-
-
-
-
-
-
-
FDA accepts Priovant's drug application for dermatomyositis treatment
-
-
-
-
-
-
-
Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
-
-
-
-
-
-
-
Organon (OGN) Completes Acquisition of Dermavant
-
-
-
-
-
-
-
Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update
-
-
-
-
-
-
-
Roivant Ranks No. 25 on Fast Company’s Fifth Annual List of the 100 Best Workplaces for Innovators and is the Winner on the Science and Technology List as a Part of the Best Workplaces for Innovator
-
-
-
-
-
-
-
Roivant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old
-
328,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

